Genedrive plc (LSE:GDR) has delivered a notable improvement in performance for the year ended June 2025, doubling revenue to £1 million and narrowing its post-tax loss to £5.2 million. The year included several key operational achievements, such as securing CE certification for the Genedrive® CYP2C19 ID Kit, enabling broader commercial rollout across the EU. The test has already been incorporated into multiple NHS initiatives and is in clinical use at centres including Salford Royal Hospital. Genedrive also received a favourable value assessment from Scotland’s Health Technology Group, paving the way for government-backed adoption of pharmacogenetic testing. Meanwhile, the Genedrive® MT-RNR1 ID Kit earned a conditional recommendation from NICE and is now deployed across a growing number of UK hospitals, with further expansion planned. Internationally, the company is advancing regulatory discussions and forging partnerships in the Middle East and the United States to extend its global reach.
Despite the strong operational progress, Genedrive continues to contend with profitability pressures. Technical indicators point to bearish momentum, and valuation metrics remain stretched due to the lack of earnings. Nonetheless, the company’s recent milestones strengthen its competitive position and could support improved prospects over time.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company focused on developing rapid, affordable, and user-friendly point-of-care diagnostic tools. Its technology helps clinicians tailor medication decisions—particularly in acute care settings—by providing fast, actionable genetic insights. The company’s flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, are designed to support safer and more effective treatment pathways.
Leave a Reply